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Table 1. Patient Demographics
Variable All Patients N549 (100%)
Patient Gender
Female 28 (57.1)
Male 21 (42.9)
Median Age at transplant 57 (19-71)
Disease / Disease status
ALL/CR1 and CR2 9
ALL/Induction failure 1
AML/CR1 and CR2 12
AML/Relapse and Induction failure 7
CML/CP1 and CP2 2
CML/ AP and BC 2
NHL 5
CLL 1
MDS 8
MPN 2
Conditioning Regimen
Reduced Intensity Fludarabine/
Melphalan
31
FTBI/Cytoxan 7
FTBI/VP-1611 11
HLA Match
10 out of 10 26
others 23
ALL; Acute Lymphoblastic Leukemia, CR; Complete Remission, CP;
Chronic Phase, AP;Accelrated Phase, BC;Blast Crisis, NHL; Non-Hodg-
kin Lymphoma, CLL;Chronic lymphocytic leukemia, MDS;Myelodysplas-
tic Syndromes, MPN; Myeloproliferative Neoplasm
S330 Poster Session IIbetter elucidate this, our group is conducting a prospective study that
evaluates the T cell receptor (TcR) Vb repertoire from patients who
are undergoing either matched related (MRD) or unrelated (URD)
donor allogeneic hematopoietic stem cell transplantation (HSCT)
for treatment of hematologic malignancies. These patients received
conditioning therapy with a regimen combining rabbit anti-thymo-
cyte globulin (Thymoglobulin, Genzyme, Cambridge, MA) and
450 cGy total body irradiation. We used a novel two-tier analysis
of TcR Vb mRNA expression in order to identify GVHD and/or
GVT-associated T cell clones: i) normalization of the TcR Vb
mRNA to CD3 mRNA rather than to housekeeping genes using
real-timeRT-PCRwhich increases sensitivity of the assay for detect-
ing minimal circulating T cell clones of interest that are activated;
ii) comparative analysis of the recipients’ TcR Vb over those of the
donors’ at the time of GVHD or GVT effects up to 1 year post-
HSCT. We then performed spectratyping analysis to confirm clon-
ality of the relevant T cell clones. We have been able to identify
T cell populations in the HSCT recipients at 90 days to 1 year fol-
lowing transplant, by demonstrating that distinct TcRVb transcripts
were significantly increased relative to the steady state expression in
the donor, in patients without GVHD or relapse vs. patients with
GVHD. In the three GVHD-free, relapse-free patients, we found
an increased expression of Vb 9 in all patients as well as an increased
expression of Vb 16 and Vb5/Vb 24 in two and one patient, respec-
tively. In 6 patients with GVHD, we observed increased expressions
of Vb4 and Vb11 in four patients and increased Vb23 in three
patients. Spectratyping analyses of each of these TcR Vb families
showed distinct skewed, mono- or oligoclonal populations, in pa-
tients with GVHD or GVHD- and relapse-free states. The identifi-
cation of these unique T cell clones in patients who have developed
GVHD or GVHD-free responses after allogeneic HSCT suggests
that they may be driven by antigen stimulation uniquely associated
with GVHD or GVT. Identification of GVHD-associated T cell
clones may offer aan opportunity for targeted therapy of GVHD
rather than using conventional immunosuppressive drugs.492
SIROLIMUS, TACROLIMUS, AND RABBIT ATG (R-ATG) AS GRAFT-VERSUS-
HOST DISEASE PROPHYLAXIS IN PATIENTS UNDERGOING UNRELATED
DONOR PERIPHERAL BLOOD HEMATOPOIETIC CELL TRANSPLANT
(HCT): EXTENDED FOLLOW UP AND UPDATED ANALYSIS
Khaled, S.K., Palmer, J., Parker, P., Nademanee, A., Snyder, D., Cai, J.-
L., Pullarkat, V., Senitzer, D., Forman, S., Nakamura, R. City of Hope,
Duarte, CA
The combined use of Sirolimus (SIR) and Tacrolimus (FK) +/2
low-dose methotrexate (MTX) recently showed a promising result
in preventing acute GVHD after unrelated donor HCT (Antin et
al. Blood 2003) although a significant number of patients still expe-
rienced chronic GVHD. In an attempt to further improve the out-
come, we have evaluated a novel combination of Tacrolimus,
Sirolimus and r-ATG (4.5 mg/kg) +/2 Methotrexate (for patients
with a mismatched donor). We have previously presented the early
results of this combination. In this report we extended the follow-
up period and updated analysis focused on 49 patients who received
PBSCT (See Table 1 for patient demographics).
Results:Engraftment rate was 91.8% (n5 45) with the median neu-
trophil engaftment at 15 days (range: 10-39). Seventeen patients
(38% of 45 engrafted) developed grade II-IV acute GVHD (grade
III 5 3, IV 5 0). Chronic GVHD developed in 23 of 38 evaluable
patients (60%, limited n 5 4, extensive n 5 19). We observed
TTP/HUS in 10 patients (20%) and one case of VOD. Eighteen
(42%) of 43 patients at risk (Recipient +ve or Donor +ve) developed
CMV reactivation, while 10 patients developed EBV reactivation
(19.6%). After a median follow up of 24 months (range: 6-48) for
33 surviving patients, the 1-year OS, DFS, and relapse rate were
75.4% (95%CI: 64.8-83.2), 73.4% (63.0-81.3), and 8.2%
(3.2-21.0), respectively. Non-relapse mortality (NRM) was 16.3%
(8.7-30.8) at 100 day and 18.4% (10.2-33.2) at 1 year. There were
no significant differences in the outcomes according to conditioning
regimens, although there was a trend for lower NRM with Flu/Mel
(9.7% vs. 27.8% at 1 year, p 5 0.06).
In summary the combination of FK/SIR with r-ATG +/2MTX
may improve the GVHD and survival outcome in this high-risk pop-ulation. However, we observed graft failure in 4 patients, which ap-
peared to be a higher rate than our historic data of approximately 2%
in the setting of unrelated donor HCT.493
NRF2 REGULATES ALLOREACTIVE T CELL FUNCTION DURING GVHD
Tsai, J.J.1, Tran, H.1, Smith, O.M.1, Yim, N.1, Rao, U.1, Takahashi, K.1,
Ghosh, A.1, Na, I.-K.2, Jenq, R.1, Hanash, A.1, Holland, A.1, van den
Brink, M.R.M.1 1Memorial Sloan-Kettering Cancer Center, New York
City, NY; 2Charite Campus Benjamin Franklin, Berlin, Germany
The activation and regulation of donor alloreactive T cells is crit-
ical for the development of graft-versus-host disease (GVHD) as well
as the regulation of graft-versus-tumor (GVT) activity. To better
understand transcriptional orchestration of alloreactive T cells, we
employed Finding Informative Regulatory Elements (FIRE)
approach, recently published by Elemento et al, to investigate gene
expression data in donor T cells in murine syngeneic (syn-) and allo-
geneic bone marrow transplant (allo-BMT) models. We discovered
the presence and absence of the motif CCGGAAG, recognized by
the transcription factor Nuclear Factor Erythroid 2-Like Factor 2
(Nrf-2), correlated to a set of genes that were slightly upregulated
in syn- and downregulated in allo-donor T cells. We hypothesized
that Nrf-2 serves as a master regulator of genes in alloreactive donor
T cells involved in the GVHD setting.
We first examined the level of expression of Nrf-2 in donor T cells
in murine syn- and allo-BMTmodels. We found that the expression
of Nrf-2 was significantly reduced only in the regulatory T cell pop-
ulation (CD4+CD25+Foxp3+) in allo-BMT (p 5 0.0004). We next
questioned the significance of Nrf-2 in alloreactive T cells. Adoptive
transfer of Nrf2-/- donor T cells leads to less GVHD morbidity, as
characterized by weight loss (p\ 0.0001) and better survival (p 5
0.0030), compared to Nrf-2+/+ donor T cells. Interestingly, loss of
functional Nrf-2 in donor T cells did not perturb their GVT activity
at the studied dose (A20, 0.25x106 per host). We demonstrated that
CFSE labeledNrf2-/- donor T cells have intact proliferation and ac-
tivation (as determined by the upregulation of CD25) upon stimula-
tion by alloantigen. Lastly, we investigated the trafficking ability of
Nrf2-/- donor T cells to gut-associated lymphoid tissues. Although
not statistically significant, there were less Nrf2-/- donor T cells in-
filtrating the mesenteric lymph nodes (MLNs) compared to Nrf2+/+
Poster Session II S331donor T cells, as measured by absolute counts (p 5 0.0650). More-
over, Nrf2-/- alloreactive T cells in spleen and MLNs expressed less
a4b7 integrin compared to Nrf+/+ T cells (16.9% versus 31.7%, re-
spectively, p 5 0.0079), indicating impaired homing ability of
Nrf2-/- alloreactive T cells.
Together, we conclude that Nrf-2 is an important mediator of al-
loreactive T cells. These data suggest that Nrf-2 could be a novel tar-
get for preventing GVHD while maintaining GVT activity and
improving overall clinical outcomes.494
NHANES III EQUATIONS FOR PFT INTERPRETATION SIGNIFICANTLY AL-
TERS BOS DIAGNOSES, SEVERITY, AND PROGNOSIS AFTER HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION (HSCT)
Williams, K.M.1, Hnatiuk, O.2, Steinberg, S.M.3, Mitchell, S.4,
Baird, K.5, Gadalla, S.M.6, Carpenter, A.1, Avila, D.1, Taylor, T.1,
Urban, A.1, Comis, L.E., Blacklock-Schuver, B.1, Gress, R.E.1,
Pavletic, S.Z.1 1National Institutes of Health, Bethesda, MD; 2National
Institutes of Health, Bethesda, MD; 3National Institutes of Health,
Bethesda, MD; 4National Institutes of Health, Bethesda, MD; 5National
Institutes of Health, Bethesda, MD; 6National Institutes of Health,
Bethesda, MD
Bronchiolitis obliterans syndrome (BOS) is a deadly manifestation
of chronic graft-versus-host disease (cGVHD) following HSCT.
The proposed BOS definition includes pulmonary function test
(PFT) parameters of: FEV1\ 75% predicted, FEV1/VC ratio\
0.7, (JAMA 2009) that are determined by reference equations.
NHANES III is the recommended standard, however, older equa-
tions are still used. We sought to determine if the clinical diagnosis
and prognosis of BOS could be predicted by FEV1 and whether the
reference equations influenced these results in a cohort of cGVHD
patients on a NIH protocol. FEV1% predicted and FEV1/FVC for
166 consecutive patients were compared using both NHANES III
and our prior reference equations (Morris/Goldman/Bates-MGB).
The resulting 4 groups were assessed for degree of agreement using
McNemar’s exact test for paired categorical data. Mortality was de-
termined using clinical records and SSDI. Assessing only FEV1%
predicted, 11% (18/166) of patients were classified as normal by
MGB(. 75%), yet abnormal by NHANES III(\75%) while 0/166
were classified as abnormal by MGB(. 75%), yet normal by
NHANES III(\75%) (p\0.0001). Evaluating only FEV1/FVC ra-
tios, 95% (157/166)were concordant by confidence interval.The dis-
cordant ratios were divided evenly between. 0.7 (n5 4) and\0.7 (n
5 5) (p 5 1.00). Using FEV1/VC ratios outside the CI identified 6
more patients who then met criteria for BOS, while 1 was removed
because MGB ratio of\ 0.7 was normal by NHANES III. Using
the amendedBOS definitionwithNHANES III classification, 12 ad-
ditional patients (29%) would have been diagnosed with BOS, and 1
would have been removed from theBOS cohort.NHANES III better
predicted oxygen requirement: 7/8 with FEV1\40% byNHANES
III and 5/8 FEV1\40%byMGB. FEV1 and 2-minute walk velocity
association calculated by either method were weak and comparable
(MGB (r 5 0.25) or NHANES III (r 5 0.24)). For patients with .
1 year of follow-up, 35% of them died (14/40). FEV1\ 35% was
a significant predictor of mortality with either equation (OR 5
20.7, p5 0.001 for NHANES III vs. 18.0, p5 0.01 for MGB equa-
tion).However, theNHANES III equation correctly predicted death
in 9 patients (64%) compared with 6 (42.8%) patients when MGB
equation was used. In conclusion, using NHANES III reference
equationsmarkedly increased the numberof casesmeetingdiagnostic
criteria for BOS and BOS cases categorized using NHANES III
improved prediction of oxygen requirement and survival.495
FEASIBILITY, SAFETY AND EFFICACY OF MARAVIROC, A CCR5 ANTAGO-
NIST, IN GRAFT-VERSUS-HOST DISEASE PREVENTION AFTER REDUCED
INTENSITY CONDITIONED (RIC) ALLOGENEIC STEM CELL TRANSPLANT
(SCT): A PHASE I/II STUDY
Reshef, R., Luger, S.M., Loren, A.W., Frey, N.V., Goldstein, S.C.,
Hexner, E.O., Stadtmauer, E.A., Smith, J., Mick, R., Heitjan, D.F.,
Hoxie, J.A., Emerson, S.G., Vonderheide, R.H., Porter, D.L. University
of Pennsylvania, Philadelphia, PACompelling data implicate the chemokine receptor CCR5 as piv-
otal in the pathogenesis of GvHD through control of lymphocyte
trafficking. We showed that maraviroc (MVC; Selzentry, Pfizer),
a CCR5 antagonist, inhibits in vitro chemotaxis, and hypothesized
that incorporating maraviroc into GvHD prophylaxis will be safe
and limit GvHD without interfering with GvL.
We initiated a phase I/II trial to determine feasibility, safety and
appropriate dose ofMVC, and to determine efficacy when combined
with standard GvHD prophylaxis after RIC SCT. 21 pts received
fludarabine and IV busulfan (6.4 mg/kg) followed by PBSCT from
matched related (6), matched unrelated (12) and 1-antigen mis-
matched unrelated (3) donors. In addition to standard tacrolimus/
methotrexate, MVC at 2 dose levels (150 and 300 mg bid) was given
from day -2 to +30.
The median age was 61 (range 21-74). Indications for SCT were
AML/MDS (10), NHL (4), MF (3), CLL, aplastic anemia, Hodgkin
lymphoma andmyeloma (1 each).MVCwas well tolerated. 3/6 pts at
the 150 mg bid dose level did not reach the targeted Cavg (100 ng/
ml), while the 300 mg bid dose level resulted in adequate Cavg in
6/6 pts and was used as the phase II dose.
The median time to ANC. 500/mLwas 13d (range 10-21) and to
plt . 20k/mL was 13d (range 11-24) with no primary graft failures.
The median whole blood donor chimerism at day 100 was 97%
(range 83-100).
The cumulative incidence of acute GvHD grade II-IV and III-IV
at day 100 is 18% (+/29.8%) and 6% (+/25.9%) respectively in this
high-risk population. Importantly, by day 100 all cases of GvHD
involved only the skin. At a median follow up of 245 days, 4/21 pts
relapsed (2 AML, 1NHL, 1MF) and 7/21 pts died (3 disease-related,
1 GvHD, 1 sepsis, 1 SOS, 1 unrelated).
Biological activity of MVC was assessed in pharmacodynamic as-
says, which test the capacity of patient serum to inhibit CCR5 inter-
nalization and chemotaxis. Patient serum from multiple time points
prevented internalization of CCR5 by RANTES. In vitro chemo-
taxis of normal donor T-cells in response to RANTES was signifi-
cantly impaired following incubation in patient serum from day
0 of transplant (on MVC) as compared to day 60 (off MVC).
Though the phase II portion of the trial is ongoing, we conclude
that MVC 300mg bid was well tolerated and biologically active.
Patients exhibited limited GvHD without excessive relapses or en-
graftment failures. Inhibition of lymphocyte trafficking represents
a promising strategy to reduce acute GvHD.496
AUGMENTED REGULATORY T CELL RESPONSE AFTER PHOTOCHEMICAL
TREATMENT ALLEVIATES ACUTE GRAFT-VERSUS HOST DISEASE AND IM-
PROVES SURVIVAL
Kanathezhath, B.1,2, Stanislaus, S.2, Kaplan, J.2, Larkin, S.2,
Kuypers, F.2, Walters, M.1,2 1Children’s Hospital & Research Institute
Oakland, Oakland, CA; 2Children’s Hospital Oakland Research Institute,
Oakland, CA
Graft-versus-Host disease (GVHD) causes significant morbid-
ity and mortality after allogeneic transplantation. Acute GVHD
early post transplantation is heralded by a cytokine storm induced
by a dominant T helper type 1(Th1) response, which damages
host tissues like skin, gut, liver and lungs. We hypothesized that
co-transplantation of photochemically (S-59) treated T cells mod-
ulates T cell effecter subsets and their cytokine milieu, and
thereby reduces acute GVHD. To this end, we transplanted
whole bone marrow cells in a major histocompatibility complex
(MHC) antigen mismatched murine model using marrow with
T cells from C57BL/6J/ AKR (acute GVHD model), with
and without S-59 treatment. We observed equivalent elevation
of CD4+Th1 (IL-2 and IFN-g), cytotoxic CD8+ (FAS, IFN-g
and TNF-a) and CD4+Th2 (IL-4, IL-5, IL-6, IL-13) cytokines
in recipients of both groups during the first week after transplan-
tation. While the Th1 cytokines persisted as long as 10 days after
transplantation, there was a shift to a regulatory T cell (Treg) cy-
tokine profile (Transforming growth factor b [TGF-b] and IL-10)
in the group that received the S-59 treated T cells. TGF-b and
IL-10 levels were higher in the peripheral blood and bone mar-
row of the study group compared to controls. This was accompa-
nied by the appearance of FoxP3High CD4+ CD25+ Tregs in the
